Capecitabine Tablet, Film Coated
Product Images NDC 31722-775

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 31722-775). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Camber Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabine150mglabel (Capecitabine150mglabel)

This is a description of Capecitabine 150mg Tablets, a hazardous drug used for treatment. The tablets should be swallowed whole with water within 30 minutes of a meal. It is essential not to crush or cut the tablets. The recommended dosage and prescribing information should be followed. The tablets should be dispensed in tight containers and stored at controlled room temperature. The manufacturer is Camber Pharmaceuticals, Inc., and contact information is provided.*

FDA Label Image

Capecitabine500mglabel (Capecitabine500mglabel)

This text is a label for Capecitabine tablets. It warns that it is a hazardous drug and gives instructions for use, like swallowing whole with water after a meal and not crushing or cutting the tablets. It also provides information on storage and contact details. The tablets contain 500 mg of Capecitabine USP and are manufactured for Camber Pharmaceuticals, Inc. by Hetero Labs Limited in India.*

FDA Label Image

Capecitabinecamberlogo (Capecitabinecamberlogo)

FDA Label Image

Capecitabinechemicalstructure (Capecitabinechemicalstructure)

FDA Label Image

Capecitabinefigure1 (Capecitabinefigure1)

FDA Label Image

Capecitabinefigure2 (Capecitabinefigure2)

FDA Label Image

Capecitabinefigure3 (Capecitabinefigure3)

This text includes information about estimated probabilities (ranging from 0.0 to 1.0) and a specific chemotherapy regimen called "5-FU + Leucovorin (Mayo Regimen)" which involves the drug Capecitabine at a dosage of 1250 mg/sqm administered twice daily intermittently.*

FDA Label Image

Capecitabinefigure4 (Capecitabinefigure4)

This text appears to be a graph showing estimated probabilities in relation to time (days) for different dosages of Docetaxel (100 mg/sqm every 3 weeks and 75 mg/sqm every 3 weeks) and Capecitabine (1250 mg/sqm twice daily intermittently). It seems to be a representation of a medical study or treatment plan using these medications.*

FDA Label Image

Capecitabinefigure5 (Capecitabinefigure5)

This text appears to contain information related to estimated probabilities and doses of different medications like Docetaxel and Capecitabine over specific time intervals. It seems to be a medical document providing details of dosage regimens for these treatments.*

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.